Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Treasury Shares (2018 - 2025)

IGC Pharma (IGC) has disclosed Treasury Shares for 8 consecutive years, with $6.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares fell 11.77% to $6.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.5 million, a 11.77% decrease, with the full-year FY2025 number at $5.8 million, down 22.22% from a year prior.
  • Treasury Shares was $6.5 million for Q3 2025 at IGC Pharma, roughly flat from $6.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $8.5 million in Q2 2023 to a low of $173000.0 in Q1 2021.
  • A 5-year average of $5.7 million and a median of $5.9 million in 2022 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: tumbled 90.65% in 2021, then surged 3322.54% in 2022.
  • IGC Pharma's Treasury Shares stood at $5.8 million in 2021, then dropped by 0.63% to $5.8 million in 2022, then skyrocketed by 47.26% to $8.5 million in 2023, then decreased by 14.77% to $7.3 million in 2024, then fell by 10.79% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Treasury Shares are $6.5 million (Q3 2025), $6.5 million (Q2 2025), and $5.8 million (Q1 2025).